Firebrick starts COVID-19 trial of Nasodine
Filed with ASX · · 3 pages · English
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
Later from Firebrick Pharma
- March 2022 Quarterly Activity Report & Appendix 4C
- Firebrick starts Phase 3 common cold trial of Nasodine
- Outcome of s60 appeal for Nasodine and next steps
- June 2022 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Annual Report
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma